AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 251 min read$AGEN

Agenus Inc. (AGEN) Reports 72% pCR in Phase 2 dMMR Colon Cancer Study

Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.

Original reporting
tradingview.com
Published Oct 25, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agenus Inc. (AGEN) Reports 72% pCR in Phase 2 dMMR Colon Cancer Study — source image
Source · tradingview.com
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The 72% pCR rate is a strong early signal that could accelerate the company's development timeline and attract partnership interest.

02

Market read

Early trial success is a catalyst for biotech stocks, potentially moving AGEN higher in the short term.

03

What to watch

Regulatory pathway and timeline for pivotal trials remain uncertain.

Relevance 9/10Novelty 9/10Timing: today

Background

Agenus (NASDAQ: AGEN) focuses on immuno‑oncology; the NEOASIS study tests its dual‑checkpoint antibodies botensilimab and balstilimab.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Agenus reported 72% pathological complete response in a Phase 2 neoadjuvant study of dMMR colon cancer.

Expected impact

likely upward pressure as investors price in the efficacy signal

Evidence & confidence

Phase 2 data are material for a biotech; however the trial is small (18 patients) and further validation is needed, tempering the impact.

Market effects

Sector

May boost sentiment for dMMR‑targeted immunotherapies and related biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Modest, confined to investors tracking oncology pipeline news.

Counterpoint

What could challenge this read

Skeptics may argue the sample size is too small to justify a price rally.

Key entities

  • company
    Agenus Inc.

    Biotech firm developing checkpoint inhibitor therapies.

Read at source← All news

Related articles

OCT 25
$AGENHighAI 8/10

After six weeks of treatment, 83% had little or no cancer remaining at surgery

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.

stocktitan.net2 min
OCT 8
$AGENHighAI 8/10

Armenia Grants First Marketing Authorizations for Agenus' BOT+BA

Agenus Inc. (AGEN) announced that Armenia granted marketing authorizations for Botvymo and Evamplix, its cancer treatments for metastatic colorectal cancer. This is the first approval for these drugs globally. The approvals are conditional and valid for one year, with potential renewals based on clinical updates. Agenus plans to evaluate seeking approvals in other Eurasian Economic Union countries.

gurufocus.com2 min
OCT 8
$AGENHighAI 9/10

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Inc. (AGEN) received Armenia's first marketing approvals for Botvymo (botensilimab) and Evamplix (balstilimab) to treat previously treated MSS metastatic colorectal cancer. Approvals were based on clinical evidence from peer-reviewed studies and major oncology conferences. Agenus may seek approvals in other Eurasian Economic Union countries. The approvals are conditional and valid for one year, renewable annually.

elliotlakestandard.ca2 min
OCT 8
$AGENHighAI 9/10

Armenia approves cancer drug combination for colorectal cancer

Agenus Inc. (AGEN) announced that Armenia's Ministry of Health approved Botvymo and Evamplix for treating specific colorectal cancer patients. The approvals, effective October 2, are based on clinical studies and are valid for one year. Agenus plans to evaluate authorizations in other Eurasian Economic Union countries. The drugs are also available in France and other countries through specific programs.

investing.com2 min